COMPASS Pathways Plc

Good day, ladies and gentlemen, and welcome to the Compass Conference third quarter call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during that session, you'll need to press star 1-1 on your phone. As a reminder, this call is being recorded, and I would now like to introduce your host for today's conference, Stephen Schultz. Sir, you may begin.

Welcome, all of you, and thank you for joining us today for our third quarter 2022 results conference call. We hope you've had a chance to review the two press releases we issued earlier today, summarizing our accomplishments this quarter and announcing the publication of the results of our Phase IIb trial for treatment-resistant depression in the New England Journal of Medicine. Again, my name is Steve Schultz, Senior Vice President of Investor Relations at Compass Pathways. I'm joined by George Goldsmith, our co-founder and executive chairman, our chief executive officer, Kabir Nath, Dr. Guy Goodwin, chief medical officer, and Mike Falvey, our chief financial officer. The call is being recorded and will be available on the Compass Pathways Investor Relations website shortly after the conclusion of the call. Before we begin, let me remind everyone that during the call today, the team will be making forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as amended. You should not place undue reliance on these forward-looking statements. Actually, events or results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties, and other factors, including those risks and uncertainties described under the heading Risk Factors in our quarterly report on Form 10Q filed with the U.S. Securities and Exchange Commission and in subsequent filings made by Compass with the SEC. Additionally, these forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update or revise any forward-looking statement, even if our estimates or assumptions change. With that, I'll now hand the call over to George Goldsmith.

Thank you, Steve, and welcome, everyone. It's with excitement and some sadness that I open this call as my final quarterly results call for Congress. I will serve as executive chairman through the end of this year. to ensure a smooth transition and to continue to serve as chairman of the board thereafter. After my comments, I will hand the baton to Kabir, who will provide the business update. Guy will then cover our clinical progress, and Mike will provide a financial review. After our prepared comments, we will open the call to questions. I am pleased to report that we've made strong progress on our journey to create the future of mental health care. Compass has been a leader in developing innovative therapies, combining a powerful investigational drug candidate, psychological support, and digital tools. We're running groundbreaking trials, already delivering promising results for treatment-resistant depression, and we're exploring new indications and avenues where clear patient need exists. We're joining forces with patients, healthcare providers, researchers, and governments. so we can forge new pathways to better mental health together. And together we have an enormous opportunity to make a difference in many people's lives. We created Comp360 Psilocybin Therapy, an investigational drug candidate combined with psychological support that could be developed into a regulatory approved therapy that patients can rely on and have that therapy reimbursed by insurance. Our groundbreaking Phase 2b trial of Comp360 psilocybin therapy in patients suffering with treatment-resistant depression provides a scientific rationale to announce a robust Phase 3 program, which has now had several clinical sites initiated. This Phase 2b trial received strong validation through today's publication in the New England Journal of Medicine. We're honored to have the leading peer-reviewed medical journal published not once but twice on Comp 360. I want to express my gratitude to those of you who have supported our work or will do so in the future. Everyone has a story. Working together, we can improve the outcomes of these stories. With that, I turn today's program over to Kabir Nath, Compass Pathways Chief Executive Officer, who will lead us through today's program. Kabir.